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Poster Session II S289with a notable recent increase in utilization for Severe Aplastic
Anemia (SAA). Recent data, although limited, has suggested
that unrelated cord blood transplantation can be a successful
treatment strategy for patients with SAA lacking a well-matched
adult donor. A retrospective analysis was performed as a means
to compare the SLCBB experience (n5 42) with published re-
sults. Outcomes data was available and evaluated for 16 singleton
cord transplants. This population included 11 pediatric and 5
adult patients. The mean age was 15.4 years (1.7-45.2). Donor/
recipient HLA matching was six of six (n5 2), five of six
(n5 8), four of six (n5 6). Median total nucleated cell dose
was 7.2  107/kg. Fourteen patients received myeloablative con-
ditioning regimens while two received non-myeloablative condi-
tioning. Thirteen patients achieved neutrophil engraftment with
a median time to recovery of 21 days (9-46). The six patients
who received a total nucleated cell dose (TNC) . 5.0  107/
kg had a median time to engraftment of 20 days as compared
to 27 days for patients receiving a TNC dose\5.0  107/kg.
There was one instance of graft failure and one patient censored
due to early death. Ten patients are alive and three have expired
from infectious complications. Acute GVHD occurred in nine
patients and chronic GVHD developed in six. Outcomes for
dual cord transplants (n5 11) were available for three patients.
All three patients engrafted with a median time to absolute neu-
trophil recovery of 25 days (22-28). These findings support that
unrelated cord blood transplant is a feasible treatment strategy
for Severe Aplastic Anemia. The SLCBB will continue to track
and report outcomes for this population.354
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFI-
BROSIS – CLOSE POST-TRANSPLANT SURVEILLANCE IS MANDATORY
Baurmann, H.1, Thiede, C.2, Burlakova, I.1, Judith, D.1, Heshmat, M.1,
Schleuning, M.1, Schwerdtfeger, R.1 1German Clinic for Diagnostics,
Wiesbaden, Germany; 2University Hospital Carl Gustav Carus, Dresden,
Germany
Introduction: Primary and post-ET/PV-myelofibrosis (MF) is
a rare myeloproliferative disorder with a very variable, on the long
term always fatal course. After allogeneic hematopoietic cell trans-
plantation (alloHCT) encouraging short term survival has been re-
ported. We present data from 57 consecutive transplants for MF in
our institution, demonstrating that close monitoring of the post-
transplant course is warranted.
Methods: Between 2000 and 2009 40 males and 17 females with pri-
mary MF (n5 48) and MF post ET or PV (n5 9) were grafted with
unmanipulated bone marrow (n5 22) or peripheral stem cells
(n5 35) from a related (n5 14) or an unrelated (n5 43) donor. Me-
dian (md) age was 54 (19-68) years. Fifteen patients (pts) had low, 28
intermediate and 14 high risk disease (Dupriez score 0, 1, 2). Karyo-
type was favorable in 35, unfavorable in 16 and unsuccessful in 6 pts.
All but four pts received intermediate intensity conditioning
(TBI(8 Gy)/Flud/Cy n5 29 or Bu(10)/Flud n5 24, standard
n5 4). In all except 4matched transplants rabbit ATGwas added be-
fore grafting.
Results: All pts engrafted at a md of 25 (11-70) days. 16 pts either
transiently or permanently lost complete chimerism during follow
up with proven relapse at a md of 376 (69 – 1211) days in 12. Overall
probability of relapse at 4 years is 32%. At a md follow up of 46 (4-
115) months probability of overall versus relapse free survival (RFS)
is 66% vs 50% for the whole cohort. Probability of RFS is signifi-
cantly less in pts with unfavorable karyotype compared to those
with favorable karyotype (21 vs 63%, p5 0.004) and for pts with cir-
culating blasts. 1% compared to those with blasts\5 1% (27 vs
61%, p5 0.002). Twelve pts with decreasing chimerism/relapse re-
ceived immunotherapy (6 PBSC boosts, 8 donor lymphocyte infu-
sions) with 8 patients responding. In 6 pts response was complete,
2 subsequently lost their response and 5 ultimately had to receive
a second transplant
Conclusions: Our results underscore the need for closely moni-
toring MF pts after alloHCT. Problems with loss of donor chi-
merism and relapse post-transplant are common however maywell respond to cellular immunotherapy. For full evaluation of
the role of alloHCT in the management of MF long term results
are warranted.355
ADDITION OF BUSULFAN TO FLUDARABINE AND TOTAL BODY IRRADIA-
TION CONDITIONED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION ENHANCES DONOR T-CELL ENGRAFTMENT AND
OPTIMIZES DISEASE CONTROL
Meyers, G., Subbiah, N., Palmbach, G., Dunn, A., Abar, F., Hayes-
Lattin, B., Gajewski, J., Kovacsovics, T., Slater, S., Jacoby, C.,
Allen, B., Maziarz, R. Oregon Health and Science University, Portland,
OR
While nonmyeloablative allogeneic hematopoietic stem cell trans-
plantation (HSCT) is associated with a reduction in treatment asso-
ciated toxicity, limitations in disease control continue to impact
overall outcomes. Key to optimizing disease remission is the rapid
integration of the donor T cell compartment to maximize graft vs.
malignancy activity. While details on the kinetics of engraftment
in nonmyeloablative HSCT is limited, reports by two groups (Baron
F. et al, Blood, 2004,104:2254 and Saito B. et al, BBMT, 2008
14:1148) concur that low donor T-cell chimerisms by Day +30 por-
tend poorer outcomes from either disease progression or engraft-
ment failure. Therefore, manipulation of the transplant procedure
to optimize engraftment outcomes early in the post-transplant
course is vital to maximize outcomes. To this end, we established
an institutional reduced-intensity regimen of busulfan 3.2 mg/kg
IV, fludarabine 90 mg/m2 and TBI 2 Gy followed by allogeneic pe-
ripheral blood stem cell transplant. Our GVHD prophylaxis regi-
men includes cyclosporine and MMF. This report describes our
early T cell chimerism data in 76 patients and shows a correlation be-
tween T cell chimerism and disease control.
The mean percentage of donor CD3+ cells was 72% at Day +28,
98% at Day +56 and 99.9% at Day +84, which compare favorably
to previous reports of engraftment with fludarabine and TBI alone.
We further analyzed chimerism data in those patients with measur-
able disease going into transplant and those with early relapse despite
remission at the time of transplant. In 13 patients that were not in
complete remission at the time of transplant, but subsequently
achieved complete remission, the mean CD3+ donor cells at Day
+28 was 85% and 92% at Day +56. This is in stark contrast to the
group of 7 patients who were in complete remission at the time of
transplant, but rapidly relapsed post-transplant, with a mean Day
+28 CD3+ donor cells of 57%, with minimal improvement to an av-
erage of 63% at Day +56, statistically significantly different from the
group achieving remission. Additional findings with this regimen in-
clude 2 year survival of 49%, with acceptable levels of GVHD.
The addition of busulfan to the backbone of fludarabine and TBI
enhances early T cell engraftment, leading to optimal disease control
by harnessing graft vs. malignancy activity. Early poor T cell chime-
risms may define those at high-risk of relapse, prompting interven-
tions to enrich donor T cell constitution.356
TARGETED IV BUSULFAN AND FLUDARABINE FOLLOWED BY POST-AL-
LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION RITUXIMAB DEM-
ONSTRATE ENCOURAGING ACTIVITY IN HIGH RISK CD20 + POSITIVE
LYMPHOID MALIGNANCIES WITHOUT INCREASED INFECTIOUS COMPLI-
CATIONS
Roman-Diaz, J.L., Pidala, J., Nishihori, T., Perkins, J., Tate, C.,
Ochoa, J., Ayala, E., Fernandez, H.F., Anasetti, C., Kharfan-
Dabaja, M.A. Moffitt Cancer Center, Tampa, FL
Rituximab has activity in lymphoid malignancies and may aug-
ment responses after allogeneic hematopoietic cell transplantation
(HCT); however prolonged lymphopenia may increase the risk
for infectious complications. We examined the safety of Rituximab
after reduced toxicity conditioning HCT. Sixteen patients (median
age 56, range 35 – 68), (CLL 7, follicular lymphoma 4, mantle cell
lymphoma3, and large cell lymphoma 2 with CD20 positive lym-
phoid malignancies. Twelve had a partial response and 4 complete
S290 Poster Session IIresponse to prior conditioning with pharmacokinetic-targeted IV
busulfan(130-145 mg/m2) and fludarabine (40 mg/m2) x 4 days (t-
IV Bu/Flu) followed by HCT. All were treated with rituximab at
375 mg/m2 on days 1 and 8 after a matched related (n5 7), mis-
matched related (n5 1), matched unrelated(n5 6), or mismatched
unrelated (n5 2) HCT. Two patients received ATG as GVHD
prophylaxis. Median time to neutrophil and platelet engraftment
was 15 and 13 days, respectively. Maximum grades of aGVHD ob-
served were 0 (n5 4), 1(n5 7), 2 (n5 7), and 3 (n5 1). Moderate/
severe cGVHD occurred in only 3/16. With a median F/U of 15
months (range: 2-33), complete response was achieved in 12, per-
sistent residual disease in 3, and progressive disease in 1. CMV re-
activation(n5 8), as well as bacterial (n5 8), fungal (n5 3), and
viral (n5 3) infection did not appear to exceed historical rates with-
out rituximab. After HCT, prolonged lymphopenia was demon-
strated: Median absolute lymphocyte counts (0.84 K/uL)
remained below the reference range through one year. In 5/16 sub-
jects for which B-cell data was available, B-cell lymphopenia per-
sisted to one year after HCT. The addition of rituximab 375 mg/
m2 to t-IV Bu/Flu followed by allogeneic HCT has encouraging
activity in the treatment of lymphoid malignancies. While both ab-
solute and B-cell lymphopenia were observed through one year
after HCT, infectious complications have not exceeded historical
rates.357
THE INCIDENCE OF HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME
(SOS) FOLLOWING A PREPARATIVE REGIMEN OF DOSE TARGETED IN-
TRAVENOUS BUSULFAN AND CYTOXAN AND A GRAFT VERSUS HOST DIS-
EASE PROPHYLACTIC REGIMEN OF TACROLIMUS AND METHOTREXATE:
A SINGLE INSTITUTION EXPERIENCE
Aljitawi, O.S.1, DuBois, L.2, O’Neal, N.2, Divine, C.1, Ganguly, S.1,
Abhaynkar, S.1, McGuirk, J.L.1 1University of Kansas Medical Center,
Kansas City, KS; 2University of Kansas Medical Center, Kansas City, KS
Hepatic sinusoidal obstruction syndrome (SOS) is a common
complication of preparative regimens in the setting of stem cell
transplantation. The use of intravenous Busulfan (Bu), however, re-
sulted in decrease in the incidence of SOS to 8%. The graft-versus-
host-disease (GVHD) prophylactic regimen seems also to impact
the risk of SOS following an ablative transplant. The goal of this
study is to determine the incidence of clinically significant SOS
in a homogenous cohort of patients who received an ablative regi-
men of dose targeted intravenous Busulfan and cytoxan (Bu/Cy),
and received tacrolimus and methotrexate (Tac/MTX) for
GVHD prophylaxis.
Methods: In this retrospective study, patients who received an
ablative regimen of intravenous Bu/Cy, and received Tac/MTX
for GVHD prophylaxis were identified. Data collected include:
age, indication for transplant, disease status at transplant, stem
cell source, date of transplant, date of onset of clinically signifi-
cant SOS, and date and cause of death. Patients who underwent
an ablative regimen of total body irradiation (TBI) and cytoxan
and received the same GVHD prophylactic regimen were used
for comparison.
Results:Between September, 2007 and August, 2009, 34 patients re-
ceived an ablative regimen of intravenous Bu/Cy and GVHD pro-
phylactic regimen of Tac/MTX. In this cohort, age ranged from
25 to 63 years old. Diagnoses were as follows: AML n5 20, MDS
n5 7, CML n5 4, myelofibrosis n5 2, and NHL n5 1. Disease
status at diagnosis was CR1 n5 16, $ CR2 n5 5, relapsed/refrac-
tory n5 2, untreated n5 6, PR n5 3, chronic phase CML n5 2.
In this cohort, only three (8.8%) patients developed clinically signif-
icant SOS. Two patients were diagnosed within 3 weeks of trans-
plant, however, one patient developed biopsy proven SOS 58 days
post transplant. None of the patients in this cohort died of SOS.
In 28 out of 34 patients, Bu pharmacokinetic (PK) studies were
done properly. In two patients the Bu dose was increased and in
one case the dose was decreased. In the comparison cohort, 29 pa-
tients received TBI/Cy conditioning regimen. In this cohort only
one patient (3.4%) developed SOS.
Conclusion:The incidence of SOS in the cohort of patients who re-
ceived dose targeted intravenous Bu/Cy and Tac/MTX for GVHDprophylaxis was comparable to the reported incidence of SOS in lit-
erature and appears to be higher than the incidence of SOS in the
TBI/Cy and Tac/MTX cohort.358
COMORBIDITY SCORE IN ALLOGENEIC MYELOABLATIVE TRANSPLANTS
CONDITIONED WITH FLUDARABINE/I.V. BUSULFAN (FLUBU4)
Patel, P., Sweiss, K., Peace, D., Quigley, J., Chen, Y.-H., Mahmud, N.,
Rondelli, D. University of Illinois at Chicago
The assessment of comorbidity score was previously demon-
strated to predict the risk of transplant related mortality (TRM) in
patients undergoing standard myeloablative allogeneic hematopoi-
etic stem cell transplantation (HSCT). Since Flu/Bu4 regimen has
been associated with limited extra-hematologic toxicity, we analyzed
whether the comorbidity score may still represent a useful tool in
transplant patients conditioned with this regimen. Of 52 consecutive
patients who received a matched HSCT with FluBu4 at our institu-
tion, 50 were evaluable for assessing their pre-transplant comorbid-
ity score according to the initial description (Sorror M et al. Blood
2005, 106:2912). The total dose of I.V. Bu was 12.8 mg/kg in 18 pa-
tients while in the remaining patients a targeted dose was given
(AUC: 4800 mM*min). Patients were divided in three groups: group
A, score 0 (n5 8); group B, score 1-2 (n5 16), group C, score$ 3
(n5 26). The three groups did not differ significantly in age, diagno-
sis, previous lines of chemotherapy, type of donor and targeted vs
standard dose of I.V. Bu. Patients with active acute leukemia at the
time of HSCT were 12% in group A, 18% in group B and 29% in
group C (p5 ns). Thirteen patients (26%) died due to relapse of
their malignancy and 11 (22%) due to transplant-related complica-
tions. TRMwas 12% in group A, 37% in group B and 15% in group
C despite the fact that the rate of acute GVHD grade II-IV was
slightly higher in group C (34%), compared to groups A (12%)
and B (31%). Patients in group C had a trend for higher relapse-re-
latedmortality, 38%, compared to 12%observed in each of the other
groups (p5 0.07). After a median follow-up of 640 days (range: 111-
2065), a greater number of patients were alive and in remission in
group A (75%) (p5 0.04), compared to group B (50%) and C
(34%). In conclusion, a higher comorbidity score correlated with
worse overall survival largely due to increased relapse. However, it
did not predict TRM in patients conditioned with FluBu4.359
CHILDREN WITH ACUTE LEUKEMIA: A COMPARISON OF OUTCOMES
FROM ALLOGENEIC BLOOD STEM CELL AND BONE MARROW TRANS-
PLANTATION
Lin, Y.-F.1, Lairson, D.R.2, Chan, W.2, Du, X.L.2, Leung, K.S.1, Ken-
nedy-Nasser, A.A.1, Martinez, C.A.1, Bollard, C.M.1,
Gottschalk, S.M.1, Heslop, H.E.1, Brenner, M.K.1, Krance, R.A.1 1Baylor
College of Medicine, Houston, TX; 2School of Public Health, University of
Texas Health Science Center at Houston, Houston, TX
The relative merits of PBSCT versus BMT for children with stan-
dard and high risk hematologicmalignancies remain unclear. In a ret-
rospective single center study, we compared allogeneic peripheral
blood stem cell transplantation (PBSCT) (n5 30) with bonemarrow
transplantation (BMT) (n5 110) in children with acute leukemia be-
tween January 1st, 2001 and September 30th, 2006. Four (13.3%)
PBSCT patients received HLA identical sibling donors versus 38
(34.5%) who received marrow: 15 (50.0%) PBSCT recipients re-
ceived HLA mismatched PBSC versus 10 (9.1%) receiving marrow.
Nine (30.0%) PBSCT patients had an HLA matched unrelated do-
nor versus 49 (44.5%) of marrow recipients. Two PBSCT (6.7%)
were from mismatched unrelated donors versus 13 (11.8%) in the
marrow recipients. The median age for PBSCT was 9 years versus
8 years for BMT. Descriptive statistics were used to summarize the
demographic and medical variables. The unadjusted probabilities
of disease-free survival were estimated using the Kaplan-Meier
method. The association of graft-source and time to each of the
study endpoints was estimated by Cox’s regressionmodel and the oc-
currence of GvHD was included as a time-dependent covariate.
Time to both neutrophil engraftment and platelet independence
